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Abstract
Many intracellular macromolecular complexes that are involved in
the production or degradation of RNAs are targeted by auto-
antibodies in systemic autoimmune diseases. RNA interference
(RNAi) is a recently characterized gene silencing pathway by which
specific mRNAs are either degraded or translationally suppressed.
In a recent issue of Arthritis Research and Therapy, Andrew
Jakymiw and colleagues reported that the enigmatic Su auto-
antigen complex contains key components of the RNAi machinery.
Anti-Su autoantibodies from both human patients with rheumatic
diseases and a mouse model of autoimmunity recognize the endo-
nucleolytic Argonaute and Dicer proteins, both crucial enzymes of
the RNAi pathway. These data raise the question of how the anti-
Su response is triggered. So far, it is unknown whether molecular
modifications may be involved, as has been proposed for other
intracellular autoantigens. The implication of RNAi in anti-viral
defence may suggest a role for virus infection in this process.
Many key regulators of gene expression were previously
shown to be targeted by the immune system in a variety of
autoimmune diseases. Patients with systemic autoimmune
diseases commonly produce antibodies against specific
classes of evolutionarily conserved nucleic acid-protein
complexes. Most frequently, the targeted proteins are either
RNA-binding themselves or associated with RNA-binding
proteins, rather than proteins associated with DNA. In many
cases, the autoantibodies were used as a tool for the
identification of the corresponding autoantigens and to
characterize their structure and function [1]. Frequently, the
prototypical autoantigens were designated with the first two
characters of the patient’s name in which autoantibodies
against them were first detected. Examples are Sm, Ro, La,
and Th/To, which represent autoantigenic targets associated
with spliceosomal U small nuclear (sn) ribonucleoprotein
particles (RNPs), the Y RNA-containing Ro RNPs, the RNA-
binding La protein, and the RNase MRP/RNase P endo-
ribonucleases, respectively. These ribonucleoprotein particles
accumulate in different subcellular compartments and play
important roles in a variety of RNA metabolic processes
(Table 1) [2]. The recent work by Jakymiw and colleagues [3]
shows that components of the RNA interference machinery
are also recognized by autoantibodies, referred to as anti-Su
antibodies.
RNA interference (RNAi) is a recently identified mechanism
by which gene expression can be controlled post-transcrip-
tionally [4]. RNAi is mediated by small RNA molecules, 21
to 25 nucleotides in length, that guide protein complexes to
complementary mRNA targets, whose expression is then
silenced. These small RNAs can be either small interfering
RNAs (siRNAs) or microRNAs (miRNAs), which derive from
long double-stranded (ds)RNA and from stem-loop
structures in long, largely unstructured transcripts,
respectively. The production and function of siRNAs and
miRNAs requires a common set of proteins, including a
protein called Dicer, which acts as a dsRNA-specific
endonuclease and is involved in the maturation of these
RNAs, and the family of Argonaute (Ago) proteins, small
RNA-binding, nucleolytic enzymes mediating the
degradation of the targeted mRNA. Ago and the siRNA or
miRNA form the core of the RNA-induced silencing complex
(RISC) [5].
The molecular identity and biological function of the Su
autoantigen remained elusive for many years. A protein of
about 100 kDa co-immunoprecipitating with GW182, a
recently identified protein required for RNAi, was hypothe-
sized by Jakymiw and colleagues [3] to be the Su auto-
antigen, which was known to migrate as a 100/102 kDa
doublet in SDS-PAGE [6]. Using a combination of immuno-
cytochemical and immunoprecipitation experiments, they
demonstrated that the Su autoantigen represents a
macromolecular complex associated with GW182 and the
RNAi pathway. The anti-Su autoimmune sera recognize
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several members of the Ago protein family, which are known
to associate into RISC and which have a high degree of
sequence identity. Targeting of the RNAi machinery by anti-
Su autoimmune sera was further supported by the
identification of a 200 kDa protein associated with the Su
antigenic complex as Dicer, the enzyme that converts dsRNA
precursors into functional siRNAs and miRNAs [5].
The disease specificity of anti-Su antibodies has been
addressed in only a few studies so far. Although they were
initially reported to be specifically associated with systemic
lupus erythematosus [7], a later study showed that auto-
antibodies to the Su antigen are found in a variety of systemic
rheumatic diseases [6]. The elucidation of the molecular
identity of the Su antigen will facilitate the determination of
the diagnostic and/or prognostic value of anti-Su antibodies.
Why are so many protein and RNA-protein complexes that
are involved in the synthesis, processing and degradation of
various classes of RNA targeted by the immune system in
systemic autoimmune diseases? One explanation might be
that under certain circumstances (e.g., during cell death)
relatively large amounts of these key components of RNA
metabolic processes are chemically modified, escape from
the cell (e.g., during necrosis) and are exposed to the immune
system. The molecular modifications may be recognized as
non-self and elicit a primary immune response in individuals
with a ‘proper’ genetic context. Environmental factors like
trauma, drugs, irradiation or viruses may be responsible for a
massive induction of cell death, either by apoptosis or
(secondary) necrosis. Especially during programmed cell
death, key regulators of gene expression are inactivated by
proteolytic cleavage or other types of modifications [8,9],
most likely to prevent them from counteracting the execution
of cell death. Via intra- and intermolecular epitope spreading,
a primary immune response targeting the modified antigen
may spread to genuine autoantigenic epitopes, the recog-
nition of which does not require molecular modifications. The
diversity of autoantibody specificities and their association
with particular diseases may be related to the combination of
genetic and environmental factors that are involved. This
hypothesis is supported by several studies demonstrating
that the molecular modifications are essential for the early
recognition by the immune system and that epitope
spreading with autoantigenic proteins/complexes occurs in
mammals [10-12].
This raises the question of whether a similar mechanism may
be involved in the anti-Su autoimmune response. Future
studies will have to clarify whether one or more of the Ago
and Dicer proteins undergo molecular changes in dying cells
and, if so, whether the resulting neo-epitopes are recognized
by early anti-Su sera.
Virus infections have been long associated with autoimmune
diseases and various mechanisms implicating viruses in the
etiology of these diseases have been proposed [13]. An
intriguing aspect of autoimmune targeting of the RNAi
machinery is that RNAi was initially recognized as an antiviral
mechanism in plants and certain invertebrates [14]. The
evolutionary conservation of RNAi suggests a similar role for
RNAi in mammals, which is indeed supported by the
production of suppressors of RNAi by mammalian viruses
[15]. Based upon these phenomena and additional evidence
for the linkage of RNAi to virus-induced cellular events,
Jakymiw and colleagues [3] argue that it is not surprising that
the components of the RNAi machinery develop into targets
of autoimmunity. On the one hand, the induction of apoptosis
as a result of the infection may lead to molecular modification
of host components, including Ago and/or Dicer. On the
other hand, the association of virus-like particles with
components of the RNAi machinery [16] may promote the
development of autoimmunity.
Conclusion
The identification of components of the RNAi machinery as
targets of the anti-Su autoantibody system provides another
example of an autoimmune response directed at a
macromolecular complex that plays a key role in the post-
transcriptional regulation of gene expression. Future studies
will have to reveal how the generation of anti-Su
autoantibodies is initiated, whether a viral factor is involved in
this process, and whether testing for these autoantibodies is
clinically relevant.
Table 1
Examples of autoantigens involved in RNA metabolic processes
Autoantigen Ribonucleoprotein complex Target protein(s) Subcellular localization Process
Sm U snRNP Sm proteins Nucleoplasm Pre-mRNA splicing
Ro Y RNP Ro60 Cytoplasm RNA quality control
La La RNP La protein Nucleoplasm Maturation RNA Pol III transcripts
Th/To RNase MRP, RNase P Rpp38, Rpp25, Rpp20 Nucleoli Pre-rRNA processing
Su RISC Ago, Dicer Cytoplasm RNAi
RISC = RNA-induced silencing complex; RNP = ribonucleoprotein particle.Page 3 of 3
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